Bicycle Therapeutics reports Q4/FY24 net loss $169M; cash $879.5M; zelenectide pevedotin shows 65% ORR in mUC

BICYCLE THERAPEUTICS PLC

2024-FY EPS reported -$2.90 revenue$35,275,000

Cash and cash equivalents $879.5M as of Dec 31, 2024, providing runway into 2H 2027.
Net loss $169.0M ($2.90 per share) for FY2024 vs $180.7M ($5.08 per share) in FY2023.
Phase 1 Duravelo-1: 65% ORR (13/20) for zelenectide pevedotin + pembrolizumab in first-line mUC; no Grade 4/5 TRAEs of interest.
FDA Fast Track granted for zelenectide pevedotin in NECTIN4-amplified TNBC and NSCLC; new Phase 1/2 trials planned in 2025.
R&D expenses $173.0M in FY2024, up from $156.5M in FY2023, driven by zelenectide pevedotin development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.